SCHEMBL16656708

SCHEMBL16656708

CN[C@H](CC(=O)O)C(C)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
GNPAT O15228 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ANPEP P15144 1/20 0.34
ENPEP Q07075 1/20 0.34
FNTA P49354 2/20 0.33
FNTB P49356 2/20 0.33
ALOX15 P16050 2/20 0.33
MAPT P10636 2/20 0.33
BMP1 P13497 1/20 0.33
KDM4E B2RXH2 1/20 0.32
THRB P10828 1/20 0.32
NFKB1 P19838 1/20 0.32
PTGS2 P35354 1/20 0.32
THPO P40225 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228271 1.00 SLC22A6 (0.38) SLC22A6TDP1CA2CA4GNPAT
SCHEMBL8368760 1.00 SLC22A6 (0.38) SLC22A6TDP1CA2CA4GNPAT
SCHEMBL27267642 0.85 GNPAT (0.44) CA2CA4GNPATSMN1; SMN2FNTA
SCHEMBL13377669 0.83 GNPAT (0.46) CA2CA4GNPATENPEPBMP1
SCHEMBL27267745 0.83 GNPAT (0.46) CA2CA4GNPATENPEPBMP1
SCHEMBL14490960 0.83 SLC22A6 (0.36) SLC22A6TDP1CA2CA4GNPAT
SCHEMBL16348723 0.83 SLC22A6 (0.36) SLC22A6TDP1CA2CA4GNPAT
SCHEMBL8729434 0.83 SLC22A6 (0.36) SLC22A6TDP1CA2CA4GNPAT
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL2220 0.82 CA2 (0.45) SLC22A6TDP1CA2CA4GNPAT
SCHEMBL13474987 0.82 ALDH1A1 (0.43) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
WO-2022257979-A1 LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE THE SCRIPPS RESEARCH INSTITUTE (US) 2022-12-15 WO disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-20210147478-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2021-05-20 US disclosed
WO-2019202052-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2019-10-24 WO disclosed
WO-2019201432-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2019-10-24 WO disclosed
US-20190322700-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2019-10-24 US disclosed
WO-2018122419-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2018-07-05 WO disclosed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147478-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII TFPI, F11, F13B SLC22A6 2005/4885TDP1 2533/4885CA2 660/4885
US-20190322700-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 SLC22A6 1267/4885TDP1 736/4885CA2 878/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 SLC22A6 1267/4885TDP1 736/4885CA2 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.